Table 1.
Demographics and Mutations by Sex and Tumor Type
| Characteristic | Adenocarcinoma (n = 115) |
Nonadenocarcinoma (n = 18) |
Both (N = 133) |
||||
|---|---|---|---|---|---|---|---|
| Female (n = 68) | Male (n = 47) | Total (n = 115) | Female (n = 8) | Male (n = 10) | Total (n = 18) | Total (N = 133) | |
| Age, mean (SD), y | 34 (5.0) | 34 (5.5) | 34 (5.2) | 33 (4.3) | 34 (4.9) | 34 (4.6) | 34 (5.2) |
| Range, y | 17–39 | 16–39 | 16–39 | 24–38 | 25–39 | 24–39 | 16–39 |
| Race, n (%)a | |||||||
| White | 49 (72.1) | 36 (74.4) | 85 (73.9) | 6 (75.0) | 6 (60.0) | 12 (66.7) | 97 (72.9) |
| Asian | 13 (19.1) | 4 (8.5) | 17 (14.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 17 (12.8) |
| Otherb | 6 (8.8) | 7 (17.1) | 13 (11.3) | 2 (25.0) | 4 (40.0) | 6 (33.3) | 19 (14.3) |
| Stage, n (%)c | |||||||
| N | 67 | 47 | 114 | 7 | 9 | 16 | 130 |
| I–III | 15 (22.4) | 3 (6.4) | 18 (15.8) | 4 (57.1) | 5 (55.6) | 9 (56.3) | 27 (20.8) |
| IV | 52 (77.6) | 44 (93.6) | 96 (84.2) | 3 (42.9) | 4 (44.4) | 7 (43.8) | 103 (79.2) |
| Mutations, n (%) | |||||||
| N | 65 | 47 | 112d | 7 | 9 | 16e | 128 |
| ALK | 21 (32.3) | 20 (42.6) | 41 (36.6) | 0 (0.0) | 1 (11.1) | 1 (6.3) | 42 (32.8) |
| EGFR | 23 (35.4) | 13 (27.7) | 36 (32.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 36 (28.1) |
| ROS1 | 7 (10.8) | 1 (2.1) | 8 (7.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (6.3) |
| Other | 14 (21.5) | 13 (27.7) | 27 (24.1)f | 7 (100.0) | 8 (88.9) | 15 (93.8)g | 42 (32.8) |
| Family history of lung cancer, n (%) | |||||||
| N | 60 | 42 | 102 | 7 | 10 | 17 | 119 |
| Yes | 18 (30.0) | 6 (14.3) | 24 (23.5) | 1 (14.3) | 3 (30.0) | 4 (23.5) | 28 (23.5) |
| No | 42 (70.0) | 36 (85.7) | 78 (76.5) | 6 (85.7) | 7 (70.0) | 13 (76.5) | 91 (76.5) |
| Ever smoked, n (%) | |||||||
| N | 61 | 43 | 104 | 7 | 10 | 17 | 121 |
| Yes | 14 (23.0) | 11 (25.6) | 25 (24.0) | 2 (28.6) | 6 (60.0) | 8 (47.1) | 33 (27.3) |
| No | 47 (77.0) | 32 (74.4) | 79 (76.0) | 5 (71.4) | 4 (40.0) | 9 (52.9) | 88 (72.7) |
| Ever used marijuana, n (%) | |||||||
| N | 60 | 43 | 103 | 7 | 10 | 17 | 120 |
| Yes | 14 (23.3) | 13 (30.2) | 27 (26.2) | 2 (28.6) | 6 (60.0) | 8 (47.1) | 35 (29.2) |
| No | 46 (76.7) | 30 (69.8) | 76 (73.8) | 5 (71.4) | 4 (40.0) | 9 (52.9) | 85 (70.8) |
| Exposure to secondhand smoke, n (%) | |||||||
| N | 60 | 43 | 103 | 7 | 10 | 17 | 120 |
| Yes | 24 (40.0) | 13 (30.2) | 37 (35.9) | 3 (42.9) | 6 (60.0) | 9 (52.9) | 46 (38.3) |
| No | 36 (60.0) | 30 (69.8) | 66 (64.1) | 4 (57.1) | 4 (40.0) | 8 (47.1) | 74 (61.7) |
Note: Denominators changed for several of the variables owing to missing data. Percentages may not add up to 100% owing to rounding.
a
Race was self-identified.
b
Five patients were black, nine were Hispanic, four were South Asian, and one was North African.
c
A chi-square test was used to determine significance of stage by adenocarcinoma (p = 0.02).
d
There were 115 patients with adenocarcinoma, but only 112 received genomic testing.
e
There were 18 patients with nonadenocarcinoma, but only 16 received genomic testing.
f
Includes four patients with a RET rearrangement, three with ERBB2 mutations, and two with MET amplification.
g
Includes one patient with a MET amplification.